123 related articles for article (PubMed ID: 38890412)
21. Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts.
Zhang L; Zhou J; Yan Y; Zhou X; Zhou Q; Du R; Hu S; Ge W; Huang Y; Xu H; Kong Y; Zheng H; Ding Y; Shen Y; Wang W
Cancer Lett; 2019 Nov; 465():36-44. PubMed ID: 31479691
[TBL] [Abstract][Full Text] [Related]
22. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
23. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
24. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
25. Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
Bao X; Wu J; Kim S; LoRusso P; Li J
J Clin Pharmacol; 2019 Jan; 59(1):20-34. PubMed ID: 30052267
[TBL] [Abstract][Full Text] [Related]
26. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
Kciuk M; Marciniak B; Kontek R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664667
[TBL] [Abstract][Full Text] [Related]
28. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
Nekkanti V; Venkateswarlu V; Ansari KA; Pillai R
Curr Drug Deliv; 2011 Nov; 8(6):661-6. PubMed ID: 22313161
[TBL] [Abstract][Full Text] [Related]
29. LifePearl microspheres loaded with irinotecan in the treatment of Liver-dominant metastatic colorectal carcinoma: feasibility, safety and pharmacokinetic study.
Maleux G; Prenen H; Helmberger T; Spriet I; Isailovic TV; Pereira P
Anticancer Drugs; 2020 Nov; 31(10):1084-1090. PubMed ID: 32932279
[TBL] [Abstract][Full Text] [Related]
30. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Tsuboya A; Kubota Y; Ishida H; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Sasaki Y; Matsumoto N; Kondo Y; Tomoda Y; Kusuhara H; Fujita KI
Cancer Chemother Pharmacol; 2021 Sep; 88(3):543-553. PubMed ID: 34117512
[TBL] [Abstract][Full Text] [Related]
31. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Fontaine SD; Carreras CW; Reid RR; Ashley GW; Santi DV
Cancer Res Commun; 2023 May; 3(5):908-916. PubMed ID: 37377899
[TBL] [Abstract][Full Text] [Related]
32. A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
LaRose M; Connolly RM; O'Sullivan CC; Velcheti V; Vilimas R; Gano K; Bates SE; Pommier Y; Thomas A
Oncologist; 2023 May; 28(5):460-e298. PubMed ID: 37010988
[TBL] [Abstract][Full Text] [Related]
33. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
34. SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy.
Naumann JA; Widen JC; Jonart LA; Ebadi M; Tang J; Gordon DJ; Harki DA; Gordon PM
Bioconjug Chem; 2018 Apr; 29(4):1111-1118. PubMed ID: 29412642
[TBL] [Abstract][Full Text] [Related]
35. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
36. Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A; Pommier Y
Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
[TBL] [Abstract][Full Text] [Related]
37. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral injection of gels containing losartan microspheres and (PLG-g-mPEG)-cisplatin nanoparticles improves drug penetration, retention and anti-tumor activity.
Yu M; Zhang C; Tang Z; Tang X; Xu H
Cancer Lett; 2019 Feb; 442():396-408. PubMed ID: 30439541
[TBL] [Abstract][Full Text] [Related]
39. New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.
Louis N; Liu S; He X; Drummond DC; Noble CO; Goldman S; Mueller S; Bankiewicz K; Gupta N; Hashizume R
J Neurooncol; 2018 Feb; 136(3):475-484. PubMed ID: 29170909
[TBL] [Abstract][Full Text] [Related]
40. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
